Antonio Lopez-Sanroman

Plain English
The study looked at how effective biological therapies are for treating inflammatory pouch disorders, such as pouchitis, Crohn's Disease of the Pouch, and cuffitis, in 145 patients. The findings showed that after 12 months, around 45% of patients treated with these therapies had significant improvement in their symptoms, with vedolizumab being particularly effective as a first option. This is important because it highlights that biological treatments can be very effective for patients whose symptoms do not improve with standard therapies and suggests that alternative treatments should be considered if initial therapies fail. Who this helps: Patients suffering from inflammatory pouch disorders.

Plain English
This study looked at different types of inflammatory pouch disorders in patients who had surgery for ulcerative colitis. Researchers followed 338 patients and found that most had pouchitis (76%), which often appears as chronic and recurrent issues. Crohn's disease of the pouch required more complex treatments, with a later diagnosis and higher use of immunosuppressants and biologics compared to pouchitis. Who this helps: This research helps patients with inflammatory pouch disorders and their doctors understand treatment needs better.

Plain English
This study looked at whether the drug vedolizumab can help prevent Crohn's disease from coming back after surgery. The researchers found that 77.8% of patients who took vedolizumab had less severe disease recurrence compared to those on a placebo, and only 23.3% of the vedolizumab group experienced severe recurrence compared to 62.2% in the placebo group. This is significant because it shows that vedolizumab can effectively reduce the chances of Crohn's disease returning after surgery, especially for patients at high risk for recurrence. Who this helps: Patients with Crohn's disease who have undergone surgery.

Plain English
This study looked at how well azathioprine works for treating inflammatory pouch disorders, such as pouchitis and Crohn's disease of the pouch. Among 63 patients, 52% showed improvement in symptoms within a year, with 30% achieving clinical remission after an average of almost two years. However, 21 patients (33%) experienced side effects, and 16 patients (25%) had to stop the treatment. Who this helps: This research benefits patients with inflammatory pouch disorders looking for effective long-term treatment options.

Plain English
This study examined how well biological treatments for inflammatory bowel disease (IBD) work and how safe they are for patients over 65. Out of 1,090 elderly patients, 57.1% achieved clinical remission after one year of treatment, and complications like cancer and infections were relatively low, with only 6.9% developing cancer during treatment. Importantly, one specific treatment called Golimumab had a higher rate of patients stopping due to inefficacy compared to the others. Who this helps: This information benefits elderly patients with IBD and their doctors by informing treatment choices.

Plain English
This study looked at how well a drug called ustekinumab works for older patients (over 60) with Crohn's disease compared to younger patients. They found that after 16, 32, and 54 weeks of treatment, both age groups had similar rates of relief from symptoms and no significant differences in side effects, except older patients had a higher risk of new cancers (4.3% compared to 0.7%). This is important because it shows that ustekinumab is just as effective for older patients, but doctors should be cautious about the increased risk of new cancers. Who this helps: This helps older Crohn's disease patients and their doctors.

Plain English
This study looked at what happens to patients with ulcerative colitis or inflammatory bowel disease after they have surgery to remove part or all of their colon. After about 10 years, 32% of these patients had to undergo unplanned surgeries, and 38% started new medical treatments to manage their condition. This is important because it challenges the idea that surgery is a complete solution for these diseases, showing that many still face ongoing health issues even after the procedure. Who this helps: This research benefits patients with ulcerative colitis and inflammatory bowel disease, as well as doctors treating these conditions.

Plain English
This study looked at how well two types of medications—anti-TNF-α agents and thiopurines—can prevent Crohn's disease from coming back after surgery. Researchers analyzed data from 645 patients across six studies and found that anti-TNF-α agents were significantly more effective, reducing the risk of the disease returning by half compared to thiopurines. This is important because it offers clearer guidance for doctors on which treatment can better help patients avoid relapsing after surgery. Who this helps: Patients recovering from surgery for Crohn's disease.

Plain English
This study looked at how commonly people with inflammatory bowel disease (IBD) take multiple medications at the same time. It found that 18.4% of the 407 patients were using five or more drugs, which is considered polypharmacy. This is more likely in older patients and those with other health issues, and it can lead to problems with sticking to their IBD treatment, even though it didn't impact disease outcomes after one year. Who this helps: This helps patients with inflammatory bowel disease and their doctors.

Plain English
This study looked at the side effects and treatment responses associated with infliximab, a medication for inflammatory bowel disease, in older patients (over 60) compared to younger patients (18 to 50). Researchers found that older patients experienced more overall side effects (23.2% vs. 19%), particularly infections (7.1% vs. 4.3%), but similar rates of specific immune-related side effects and treatment failure compared to younger patients. This matters because it suggests that while elderly patients have higher side effects, their treatment effectiveness with infliximab is comparable to that of younger patients. Who this helps: This helps patients with inflammatory bowel disease, especially those over 60, and their doctors in making informed treatment choices.

Plain English
This study looked at how well different methods for screening latent tuberculosis infection (LTBI) work for patients with inflammatory bowel disease (IBD) who are about to start anti-TNF therapy. Researchers found that out of nearly 7,600 patients screened, 19% had LTBI, and using a combination of dual screening tests or performing screenings earlier significantly improved the detection rate, with the best results occurring when both methods were used together. This is important because identifying and treating LTBI can help prevent tuberculosis in patients who are getting treatments that weaken their immune systems. Who this helps: This helps patients with inflammatory bowel disease.

Plain English
This study looked at how the gut lining changes over time in patients with severe ulcerative colitis who did not respond to steroids but were treated with either infliximab or cyclosporine. Among 55 patients, 83% had serious symptoms at the start, but by day 98, 73% of those treated with infliximab reached full improvement, compared to only 25% of those on cyclosporine. The findings show that bleeding improves sooner than other symptoms, and infliximab is more effective for helping patients heal from this serious condition. Who this helps: This helps patients with severe ulcerative colitis and their doctors in choosing more effective treatment options.

Plain English
This study looked at tofacitinib, a new medication for treating moderate to severe ulcerative colitis, which is an inflammatory bowel disease. The researchers found that tofacitinib effectively targets specific parts of the immune system, showing it has a good safety profile and can be taken easily as a pill. This is important because it offers a new way to manage a challenging condition for many patients. Who this helps: This benefits patients with ulcerative colitis.

Plain English
This study looked at how well the medication tofacitinib works for patients with ulcerative colitis in real-life situations. They found that 60% of patients showed some improvement and 31% were in remission after 8 weeks of treatment. However, many patients stopped taking the drug, often because it didn’t work for them right away, highlighting the need for better management of this condition. Who this helps: This helps patients with ulcerative colitis and their doctors in choosing treatment options.

Plain English
Researchers studied patients who developed acute pancreatitis caused by drugs at a medical center over ten years. They found that drug-induced pancreatitis accounted for 2.8% of all acute pancreatitis cases, with thiopurines being the most common drug involved in 61.8% of these instances. Most patients had mild cases, and only 2.3% experienced a recurrence of the condition, highlighting that drug-related pancreatitis tends to happen within the first month of treatment but is generally not severe. Who this helps: This information is useful for doctors and patients prescribed potentially risky medications.

Plain English
This study looked at how well methotrexate works for patients with Crohn's disease who didn't improve with previous treatments called anti-TNF-α. They followed 110 patients and found that 60% had a good short-term response to methotrexate, while 30.9% achieved remission. Over time, 82% of those who continued treatment after 16 weeks maintained their improvement at 12 months, although 44% experienced side effects, and 30.4% had to stop the medication because of them. Who this helps: This research benefits patients with Crohn's disease who have not responded to other treatments.

Plain English
This study looked at whether testing the immune response of ulcerative colitis patients could help choose better donors for fecal microbiota transplantation (FMT), a treatment designed to restore healthy gut bacteria. Researchers found that despite assessing immune reactions from patients and multiple donors, the treatment did not lead to improvements in the patients' symptoms or disease remission after 16 weeks. This matters because it indicates that using immune tests to select donors for FMT may not be effective for patients with ulcerative colitis. Who this helps: This helps patients with ulcerative colitis seeking effective treatments.

Plain English
This study examined how effective and safe a procedure called endoscopic balloon dilation (EBD) is for patients with inflammatory bowel disease (IBD), particularly those with Crohn's disease and ulcerative colitis. Out of 187 patients treated, the procedure worked well for 79.5% of the cases, and 78.1% experienced positive results over an average follow-up period of 40 months. The findings indicate that EBD can be effectively performed in various hospitals, offering a potential treatment option for patients with short blockages in their intestines. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study looked at how well a procedure called endoscopic balloon dilation works for patients with inflammatory bowel disease (IBD). Researchers found that this treatment is effective, helping about 70% of patients improve their symptoms without serious complications. This is important because it offers a less invasive option for managing IBD, which can greatly affect a person's quality of life. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study looked at whether giving anti-TNF treatments (like infliximab and adalimumab) less often than usually recommended is effective for patients with inflammatory bowel disease (IBD). Researchers found that of the 85 patients studied, 59% (or 50 patients) successfully maintained their treatment plan without needing to increase the dose or switch medications over a median follow-up of 34 months after starting a spaced-out schedule. This approach could make treatment easier and less costly for IBD patients who are doing well and have been treated early. Who this helps: Patients with inflammatory bowel disease looking for more flexible and affordable treatment options.

Plain English
This study looked at patients with inflammatory bowel disease (IBD) who experienced a first episode of acute pancreatitis (AP) but had no clear cause for it. Out of 185 patients, 38 (20.6%) were found to have idiopathic acute pancreatitis (IAP). The study revealed that IAP is most common in patients with ulcerative colitis and has a high risk of reoccurrence, with a 28% chance of another episode within five years. This is significant because it highlights the need for follow-up tests to identify potential underlying causes in these patients. Who this helps: This study benefits patients with inflammatory bowel disease and their doctors by guiding them in monitoring and treating pancreatitis.

Plain English
The study looked at the use of tacrolimus, a drug typically used after organ transplants, in treating inflammatory bowel disease (IBD). After three months, patients with ulcerative colitis showed improvement, with their symptoms reducing from a score of 6 to 3, and those with Crohn's disease improved from 9 to 7. However, many patients stopped taking the drug within two years due to losing effectiveness or experiencing side effects, linking this to high drug levels in the blood, and 39% needed surgery. Who this helps: This research benefits patients with inflammatory bowel disease and their doctors by providing insights into tacrolimus treatment.

Plain English
Researchers studied how new biological treatments for inflammatory bowel diseases (IBD), like Crohn's disease (CD) and ulcerative colitis (UC), affect the need for early surgeries. They found that after these treatments were made available, the need for surgery in Crohn's patients significantly decreased, with only 11% requiring surgery within three years compared to 16% before the treatments were introduced. However, for ulcerative colitis patients, the surgery rates remained about the same, showing that the new treatments mostly benefited those with Crohn's disease. Who this helps: This helps patients with Crohn's disease and their doctors by reducing the need for surgeries.

Plain English
This study looked at inflammatory bowel disease (IBD) among Roma/Gypsy patients in Spain, comparing them to Caucasian patients. They found that 43% of the Roma/Gypsy patients had family members also affected by IBD, compared to only 9% of Caucasian patients. Additionally, Roma/Gypsy patients typically experienced more severe forms of the disease and needed more treatments, including medications and surgery. Who this helps: This research benefits Roma/Gypsy patients and their healthcare providers by improving understanding of their unique health needs.

Plain English
In the APPRECIA trial, researchers studied the quality of life in patients with Crohn's disease after they underwent surgery to remove part of their intestine. They found that, after one year, patients taking either adalimumab (ADA) or azathioprine (AZA) experienced significant improvements in their quality of life as measured by two questionnaires. Specifically, only those without signs of disease returning (endoscopic recurrence) showed meaningful quality of life benefits by the end of the year, highlighting the importance of keeping the disease in remission for better overall health. Who this helps: This helps Crohn's disease patients who undergo surgery by showing the importance of effective post-operative treatment in improving their quality of life.

Plain English
This study looked at cases of colitis caused by the cancer treatment nivolumab, which can appear similar to ulcerative colitis. Researchers found six new cases of nivolumab-induced colitis, bringing the total to 19 cases when including previous reports. They found that while most patients improved with steroid treatment, about 25% required additional therapy, and some had intestinal infections. This matters because it highlights the importance of correctly diagnosing and treating this side effect, as it can be confused with other diseases. Who this helps: This helps patients receiving nivolumab and their doctors.

Plain English
This study looked at how the use of corticosteroids, a common treatment for Inflammatory Bowel Disease (IBD), affects the risk of complications after surgery. It found that patients who are on steroids when they have surgery face a higher chance of complications, both from infections and other issues. This matters because understanding these risks can help doctors better prepare and manage patient care before surgery to improve outcomes. Who this helps: This helps patients with IBD and their doctors.

Plain English
This study looked at patients with primary sclerosing cholangitis (PSC) who also had inflammatory bowel disease (IBD) to find out how common PSC is among them and what treatment options are being used. They found that 277 out of every 100,000 IBD patients develop PSC, primarily affecting men and those suffering from ulcerative colitis. The study revealed that patients showing symptoms of PSC when diagnosed have a higher risk of developing colorectal cancer, while those with more severe forms of PSC had worse outcomes. Who this helps: This research benefits patients with IBD and their doctors by highlighting the importance of monitoring for cancer risks associated with PSC.

Plain English
This study focused on how to improve access to faecal microbiota transplantation (FMT) for patients suffering from recurrent infections like C. difficile. Experts from various countries agreed on important guidelines for setting up stool banks, which would help ensure safe, reliable access to FMT by standardizing donor selection, stool processing, and ongoing monitoring. This is important because it could lead to more patients receiving effective treatment for infections that are hard to manage with standard medications. Who this helps: This helps patients who need FMT, particularly those with recurrent C. difficile infections.

Plain English
The study looked at the long-term effectiveness of two treatments, ciclosporin and infliximab, for patients with a severe form of ulcerative colitis that didn't improve with steroids. After about 5 years, around 61.5% of patients who received ciclosporin and 65.1% who received infliximab were still able to avoid surgery for their condition. This is important as it shows that both medications offer similar long-term outcomes and safety, giving doctors and patients valuable options for managing this serious illness. Who this helps: Patients with steroid-refractory acute severe ulcerative colitis.

Plain English
This research looks at how to treat Crohn's disease when it causes complications around the anus, which can be very painful and costly for patients. The findings show that drugs called anti-TNF (like infliximab and adalimumab) are the first choice for treatment, but about half of the patients still don't get better. New treatments being explored include other biological drugs and stem cells, which could help heal stubborn cases without causing systemic side effects. Who this helps: This information benefits patients with Crohn's disease facing complications, as well as their doctors in making treatment decisions.

Plain English
This research paper discusses the use of thiopurines—specifically azathioprine and mercaptopurine—in treating inflammatory bowel disease (IBD). The findings highlight that while thiopurines help maintain remission in some patients, about 30-40% don't respond to treatment and 10-20% experience negative side effects. It recommends careful monitoring of patients, including checking for infections and adjusting dosages to minimize risks, since some serious conditions like certain cancers have been linked to long-term use. Who this helps: This benefits patients with inflammatory bowel disease and their doctors.

Plain English
This study looked at how effective and safe autologous stem cell transplantation (AHSCT) is for patients with severe Crohn's disease that does not respond to typical treatments. Out of 82 patients treated across Europe, 68% experienced significant symptom improvement after the transplant, and 27% required no further medication afterward, with a follow-up time averaging about 41 months. This matters because it shows AHSCT can provide lasting relief for difficult cases of Crohn's disease, offering hope for patients who have already tried multiple treatments without success. Who this helps: Patients with severe, treatment-resistant Crohn's disease.

Plain English
This study looked at how effective oral budesonide is for treating Crohn's disease, a type of inflammatory bowel disease. The researchers reviewed its use and found that budesonide mainly targets inflammation locally in the gut, making it an important option for managing symptoms and improving patient outcomes. This is significant because using the right medication can lead to better quality of life for patients with Crohn's disease. Who this helps: This helps patients with Crohn's disease and their healthcare providers.

Plain English
This study looked at how well anti-TNF drugs, which are commonly used to treat inflammatory bowel disease (IBD) like Crohn's disease and ulcerative colitis, work in situations beyond just the usual intestinal inflammation, such as complications like strictures or extraintestinal issues. The review found that while these drugs are effective for some complications, there is less solid evidence for their effectiveness in other cases, like stricturing or penetrating types of Crohn's disease. Understanding these limits is important because it helps doctors know when these medications are most likely to help their patients. Who this helps: This helps doctors and patients dealing with complex IBD complications.

Plain English
This study looked at how measuring specific metabolites of thiopurine drugs can improve treatment for patients with inflammatory bowel disease who weren’t responding well to their medication. It found that 45.6% of patients were on doses that were too low, and 16.2% were on doses that were too high. By adjusting the treatment based on these measurements, the study showed that nearly 75% of patients could be managed effectively without switching to more expensive medications. Who this helps: This benefits patients with inflammatory bowel disease and their doctors by providing a more tailored approach to treatment.

Plain English
This study looked at how ulcerative colitis (UC) affects the social and professional lives of patients in Spain. Out of 585 patients surveyed, 75% responded, revealing that 65% felt their disease impacted their leisure activities, and nearly half reported it affected their job choices or caused them to lose jobs. This is important because it highlights the significant, often overlooked consequences of UC on daily life, underscoring the need for better support and treatment to improve patients' quality of life. Who this helps: This helps patients with ulcerative colitis and their healthcare providers.

Plain English
This study looked at how mesalazine, a medication for ulcerative colitis, is used by patients in Spain, including the doses prescribed and how well patients stick to their treatment. Out of 203 patients, the average dose was about 2.6 grams per day, with half of them taking high doses of 3 grams or more; most patients reported good adherence to treatment, with 81.8% staying on track. The findings suggest that higher doses may be a successful approach for maintaining treatment in ulcerative colitis. Who this helps: This helps patients with ulcerative colitis and their doctors in managing their treatment effectively.

Plain English
This study looks at complex perianal disease in patients with Crohn's disease, which can severely affect their quality of life. It highlights that while many cases can be managed effectively, this aggressive form leads to a lot of complications, and a team of doctors working together is essential for the best care. New treatment options are also reviewed to improve how these patients are treated. Who this helps: This helps patients with complex perianal Crohn's disease and their healthcare providers.

Plain English
This study looked at how patients with inflammatory bowel disease (IBD) are more likely to get infections due to weak immune systems, frequent doctor visits, and surgeries. It found that these infections are a major cause of illness and death for these patients and are often hard to spot and treat. Understanding these infections better can help doctors provide safer and more effective care for IBD patients. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study compared two medications, adalimumab and azathioprine, to see which is better at preventing Crohn's disease from coming back after surgery. Out of 91 patients, 42.2% of those taking adalimumab experienced a recurrence of their disease, compared to 59% of those taking azathioprine. Although adalimumab did not perform significantly better in preventing recurrences, patients tolerated it much better, with only 4.4% stopping due to side effects compared to 23.2% with azathioprine. Who this helps: This information helps doctors and patients with Crohn's disease make informed choices about medication after surgery.

Plain English
This study looked at how well a procedure called fecal microbiota transplantation (FMT) works for patients with repeated Clostridium difficile infections (CDI) in Spain. Of the 12 patients treated, 11 (about 92%) had their infections resolved after just one FMT session, showing that the treatment is not only effective but also safe, with no major side effects reported. This is important because it offers a new, effective option for patients struggling with a stubborn infection that typically doesn't respond to other treatments. Who this helps: Patients suffering from recurrent Clostridium difficile infections.

Plain English
This study looked at how well Spanish patients with ulcerative colitis understand their disease and how easily they can see a specialist. Out of 585 patients surveyed, 436 responded, revealing that while 89% get their information mainly from their doctors, between 32% and 80% still lack important knowledge about their condition. Importantly, patients at smaller hospitals reported better understanding and easier access to their doctors during flare-ups compared to those at larger hospitals. Who this helps: This benefits patients with ulcerative colitis, particularly those treated at smaller healthcare facilities.

Plain English
This study focused on how to best monitor, prevent, and treat the re-emergence of Crohn's disease in patients after they have surgery. Researchers found that even with new drugs, about 50% of patients experience a return of symptoms within weeks of their operation, which can lead to further surgeries and complications like short bowel syndrome. These findings emphasize the need for better strategies in managing post-surgery care to improve patient outcomes. Who this helps: This information helps patients with Crohn's disease and their doctors in managing their treatment after surgery.

Plain English
This study brought together 28 experts from 10 countries to create guidelines for using faecal microbiota transplantation (FMT) in treating infections and other gut-related disorders. They found that FMT is a promising treatment but requires standardized procedures for safety and effectiveness. Their recommendations aim to help doctors implement FMT more widely and effectively, ensuring that the treatment is both safe and regulated. Who this helps: This helps patients suffering from infections and gut-related disorders.